With a focus on a 2030 revenue target, AstraZeneca Plc presented 2024 financial results on 6 February which exceeded expectations but also threw up some risks. Group revenue for 2024 was $54.1 billion, up by 18% at actual exchange rates and by 21% at constant rates, buoyed by double-digit increases across the portfolio. This included sales of drugs for cancer, cardiovascular, renal, metabolic, and respiratory diseases as well as for rare conditions.
